The Phase 3 clinical development program for Zerenex^TM (ferric citrate) for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis was conducted under a Special Protocol Assessment (SPA) agreement with the FDA and was completed in January 2013.

In November 2012, the Company initiated a Phase 2 clinical study of Zerenex^TM for the Treatment of Patients with Non-Dialysis Dependent Chronic Kidney Disease. For more information on this Phase 2 study, which is currently ongoing, please click HERE to be directed to the listing at clinicaltrials.gov.